The modest response to EZH2 inhibition was validated in vivo using an NEPC patient-derived xenograft (PDX) model (WCM12) where we found that the tumor growth rate was not significantly impacted when treated with tazemetostat compared to vehicle (Fig. 1B). This evidence concerns the gene EZH2 and neoplasm.